Clinical trials: Bacteraemia
Pseudomonas
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia
Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity.
- Trial name
- Mero-Pyo (NCT06113107)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of…
- Trial name
- NCT01701219
- Testing
- Ceftaroline fosamil
- Where
- 27 sites in United States
- Volunteers
- 56 people
- Sponsor
- Forest Laboratories
Gram Negative Bacteremia
Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia
The investigators plan an open label randomized controlled trial to compare short-course antibiotic therapy (<=7 days) versus longer treatment (>7 days).
- Trial name
- NCT01737320
- Testing
- short-course antibiotic treatment, accepted prolonged antibiotic treatment
- Where
- 3 sites in Israel, Italy
- Volunteers
- 604 people
- Sponsor
- Rabin Medical Center
Gram-negative Bacteremia, Urinary Tract Infection Bacterial
Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia
GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram negative bacteremia with a…
- Trial name
- GNB5 (NCT04291768)
- Testing
- Shortened antibiotic treatment, Standard antibiotic treatment
- Where
- 13 sites in Denmark
- Volunteers
- 380 people
- Sponsor
- Thomas Benfield
Pneumonia, Meningitis
Lebanese Interhospital Pneumococcal Surveillance Program
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection.
- Conditions
- Pneumonia, Meningitis, Sepsis, Bacteremia
- Trial name
- LIPSP (NCT00901602)
- Where
- Lebanon
- Volunteers
- 700 people
- Sponsor
- American University of Beirut Medical Center
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Endotoxemia, Muscle Loss
Anabolic Potential of 3-hydroxybutyrate (3-OHB) and Whey Protein in a Human Catabolic Inflammatory Disease Model
This study aims to investigate the muscle anabolic potential of adding ketone (3-hydroxybutyrate) to whey protein compared with isocaloric, isonitrogenous whey protein in a human model of inflammatory catabolic disease.
- Conditions
- Endotoxemia, Muscle Loss, Catabolic State, Protein; Disease
- Trial name
- NCT04064268
- Testing
- Whey, 3-OHB + Whey
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Endotoxemia
A Possible Therapeutic Role for Adenosine During Inflammation
The adenosine receptor is known for its anti-inflammatory actions and could therefore be a potential target in the treatment of sepsis and septic shock.
- Trial name
- NCT00513110
- Testing
- AMPD1 polymorphism, Caffeine infusion
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Staph Aureus Methicillin Resistant Bacteremia
Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.
- Trial name
- NCT01898338
- Testing
- Fosfomycin 2gr/6h iv, Daptomycin 10mg/kg/24h iv
- Where
- 18 sites in Spain
- Volunteers
- 167 people
- Sponsor
- Miquel Pujol
Bacteremia
Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change
The purpose of this study is to investigate the risk factor, molecular character and susceptibility change for recurrent ESBL-producing Enterobacteriaceae bacteremia
- Trial name
- NCT01392118
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Chang Gung Memorial Hospital
Infective Endocarditis, Endocarditis, Bacterial
Combined Rehabilitation and Nutritional Support vs. Standard Care in In-Hospital Endocarditis Treatment
Infective endocarditis (IE) is associated with high morbidity and mortality. Patients with IE are affected by a lengthy hospitalization, leading to physical deconditioning and a rapid decline in physical fitness, muscle mass and…
- Conditions
- Infective Endocarditis, Endocarditis, Bacterial, Infection; Heart, Bacteremia
- Trial name
- ENDOCARE (NCT06563609)
- Testing
- Intensive physical Therapy, Probiotic treatment, Individualised Nutritional Support
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Johannes Grand
Endotoxemia, Systemic Inflammatory Response
PK/PD of EA-230 During Endotoxemia
EA-230 is a newly developed synthetic compound with anti-inflammatory properties. Pre-clinical data indicate that EA-230 may be a valuable treatment for systemic inflammation resulting from a variety of causes such as surgery…
- Trial name
- NCT02629874
- Testing
- EA-230, Endotoxin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Gram-Positive Bacterial Infections
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.
- Trial name
- NCT00055198
- Testing
- daptomycin
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacteraemia Post Debridement
PVP Iodine Effect on Post Debridement Bacteraemia
The study investigates the effect of supra- and subgingival rinsing of 10% PVP prior to ultrasonic debridement in patients with periodontitis (as compared to rinsing with water) in terms of post treatment bacteraemia.
- Trial name
- PJB 1 (NCT01647347)
- Testing
- Supra- and subgingival rinsing with 10% PVP-iodine, Water
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Renal Dialysis, Catheter-Related Infections
Taurolidine in Haemodialysis Catheter Related Bacteraemia
The purpose of this study is to determine whether taurolidine with heparin locking solution prevents recurrence of central venous catheter related blood stream infections in haemodialysis patients.
- Trial name
- NCT01243710
- Testing
- Taurolidine with heparin (500 units/ ml)
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Imperial College Healthcare NHS Trust
Muscle Protein Synthesis, Endotoxemia
Whey vs Casein to Combat Post-inflammatory Protein and Muscle Waste in Acute Disease
This study compares three different protein supplements (casein, whey and leucine-enriched whey) and their effect on post-inflammatory muscle waste in a model of acute disease.
- Conditions
- Muscle Protein Synthesis, Endotoxemia, Nutrition, Milk Protein
- Trial name
- NCT03319550
- Testing
- Casein, Whey, Leucine-enriched whey
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Staphylococcus Aureus Bacteremia
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will…
- Trial name
- SABEDTIO (NCT07148960)
- Testing
- Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- West Virginia University
Septic Shock, Candidiasis
Candida Host Defense Response After Septic Shock in the Critically Ill
Septic shock is associated with acquired immunoparalysis which is associated with a high risk of nosocomial acquired infection. Nosocomial candidiasis is associated with a 50% rate of mortality but is difficult to diagnose.
- Trial name
- IMMUNOCANDIDA (NCT03136081)
- Testing
- Candidiasis infection occurence
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bacteremia, Infective Endocarditis
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
The goal of this prospective interventionist cohort study is to assess the prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia at low risk of this complication.
- Trial name
- ET-AUREUS (NCT05862025)
- Testing
- Echocardiography evaluation
- Where
- Spain
- Volunteers
- 470 people
- Sponsor
- Puerta de Hierro University Hospital